Vitiligo: nieuwe inzichten in pathogenese en therapie

M. W. Bekkenk

Vitiligo: nieuwe inzichten in pathogenese en therapie

M. W. Bekkenk^*

^*Corresponding author for this work

Department of Clinical Genetics, Amsterdam UMC, Amsterdam, The Netherlands

Research output: Contribution to journal › Article › Professional

Abstract

The at this moment available treatment options for vitiligo are considered insufficient by the majority of patients. The recent discovery of resident memory T cells as key players in vitiligo pathogenesis results in new treatment options. The Lancet publication on the results of the phase 2 study on the topical jak (1 and 2) kinase inhibitor ruxolitinib in patients with non-segmental vitiligo marks a new step towards more effective therapy for vitiligo patients.

Original language	Dutch
Pages (from-to)	44-45
Journal	Nederlands tijdschrift voor dermatologie en venereologie
Volume	31
Issue number	8
Publication status	Published - 2021

Cite this

@article{328041f2beb648e1a73a156150bec2b0,

title = "Vitiligo: nieuwe inzichten in pathogenese en therapie",

abstract = "The at this moment available treatment options for vitiligo are considered insufficient by the majority of patients. The recent discovery of resident memory T cells as key players in vitiligo pathogenesis results in new treatment options. The Lancet publication on the results of the phase 2 study on the topical jak (1 and 2) kinase inhibitor ruxolitinib in patients with non-segmental vitiligo marks a new step towards more effective therapy for vitiligo patients.",

author = "Bekkenk, \{M. W.\}",

year = "2021",

language = "Dutch",

volume = "31",

pages = "44--45",

journal = "Nederlands tijdschrift voor dermatologie en venereologie",

issn = "0925-8604",

publisher = "DCHG Partners in Mediscne Communicatie",

number = "8",

}

TY - JOUR

T1 - Vitiligo

T2 - nieuwe inzichten in pathogenese en therapie

AU - Bekkenk, M. W.

PY - 2021

Y1 - 2021

N2 - The at this moment available treatment options for vitiligo are considered insufficient by the majority of patients. The recent discovery of resident memory T cells as key players in vitiligo pathogenesis results in new treatment options. The Lancet publication on the results of the phase 2 study on the topical jak (1 and 2) kinase inhibitor ruxolitinib in patients with non-segmental vitiligo marks a new step towards more effective therapy for vitiligo patients.

AB - The at this moment available treatment options for vitiligo are considered insufficient by the majority of patients. The recent discovery of resident memory T cells as key players in vitiligo pathogenesis results in new treatment options. The Lancet publication on the results of the phase 2 study on the topical jak (1 and 2) kinase inhibitor ruxolitinib in patients with non-segmental vitiligo marks a new step towards more effective therapy for vitiligo patients.

UR - https://www.scopus.com/pages/publications/85177670170

M3 - Article

SN - 0925-8604

VL - 31

SP - 44

EP - 45

JO - Nederlands tijdschrift voor dermatologie en venereologie

JF - Nederlands tijdschrift voor dermatologie en venereologie

IS - 8

ER -

Vitiligo: nieuwe inzichten in pathogenese en therapie

Abstract

Other files and links

Cite this